Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06894329 · ClinicalTrials.gov registry record
A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
A clinical trial of Pancreatic Cystic Lesions, sponsored by Amplified Sciences.
- Recruiting
- Registry status
- 50
- Enrollment target
- 3
- Study locations
NCT06894329 is a study of Pancreatic Cystic Lesions that is actively recruiting participants, run by Amplified Sciences. The registered enrollment target is 50 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06894329, a study of Pancreatic Cystic Lesions, is actively recruiting participants, sponsored by Amplified Sciences.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.
Conditions Studied
Study Locations (3)
Indiana
- Indiana University - Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Rutgers Health - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06894329
The ClinicalTrials.gov registry entry for NCT06894329 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amplified Sciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cystic Lesions appearing as the primary indexed condition, and to 0 interventions.
NCT06894329 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06894329 about?
NCT06894329 is a clinical study titled "A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions". The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test...
What is the current status of trial NCT06894329?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-02-17. Estimated completion is 2027-06-30.
What conditions does trial NCT06894329 study?
This clinical trial studies the following conditions: Pancreatic Cystic Lesions.
Who is sponsoring clinical trial NCT06894329?
This trial is sponsored by Amplified Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06894329 being conducted?
This trial has 3 study locations across Indiana, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cystic Lesions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.